BIO Seminar: Prof. Ines Thiele

​"Large-scale modelling of the human microbiome accounts for strain-specific drug metabolism"


​​​Welcome to the BIO seminars, an open seminar series from the Department of Biology and Biological Engineering, where we meet to listen to internationally renowned speakers from research fields relevant to BIO.

After the lecture, at 15:00, it will be possible to meet Ines Thiele in break-out session.
Preregistration is required via email to Stefan Hohmann. ​

About Ines Thiele

Ines Thiele is the principal investigator of the Molecular Systems Physiology group at the National University of Ireland, Galway. Her research aims to improve the understanding of how diet influences human health. Ines earned her PhD in bioinformatics from the University of California, San Diego, in 2009. From 2009 until 2013, Ines was an Assistant Professor at the University of Iceland. From April 2013 until January 2019, she was an Associate Professor at the University of Luxembourg. Since February 2019, Ines is a Professor for Systems Biomedicine at the National University of Ireland, Galway. In 2013, Ines Thiele received the ATTRACT fellowship from the Fonds National de la Recherche (Luxembourg). In 2015, she was elected as EMBO Young Investigator. In 2017, she was awarded the prestigious ERC starting grant. She is an author of over 80 international scientific papers and reviewer for multiple journals and funding agencies.  

Abstract

The human microbiome influences the efficacy and safety of a wide variety of commonly prescribed drugs, yet comprehensive systems-level approaches to interrogate drug-microbiome interactions are lacking. I will present a computational resource of human microbial genome-scale reconstructions, deemed AGORA2, which accounts for 7,206 strains, includes microbial drug degradation and biotransformation, and was extensively curated based on comparative genomics and literature searches. AGORA2 extends its predecessor, AGORA1, both in genome and metabolic content coverage. I will show that the microbes can use the drug molecules as carbon- and energy sources. Using microbial community modelling with metagenomic data from a cohort of 616 colorectal cancer patients and controls, I will show that the individual microbiomes have different drug conversion potential in silico. This analysis revealed that some drug activation capabilities were present in only a subset of individuals, and that drug conversion potential correlate with clinical parameters. Thus, AGORA2 paves the way towards personalised, predictive analysis of host-drug-microbiome interactions.
Category Seminar
Location: via Zoom; register for link and password
Starts: 09 December, 2020, 14:00
Ends: 09 December, 2020, 16:00

Published: Wed 25 Nov 2020.